Clinical experiences in Turkish paediatric patients with chronic recurrent multifocal osteomyelitis

Betül Sözeri1, Nuray Aktay Ayaz2, Başak Yıldız Atıkan3

  • 1Division Pediatric Rheumatology, Health Sciences University, Istanbul Umraniye Training and Research Hospital, İstanbul, Turkey.

Insights

Chronic recurrent multifocal osteomyelitis (CRMO) in children often requires long-term management. Anti-inflammatory drugs show limited efficacy, necessitating diverse therapeutic strategies for pediatric patients.

Area of Science:

  • Pediatric Rheumatology
  • Osteomyelitis Research
  • Clinical Immunology

Background:

  • Chronic recurrent multifocal osteomyelitis (CRMO) is a rare pediatric condition with uncertain etiology.
  • Characterized by recurrent, prolonged episodes of bone pain in children and adolescents.
  • Current understanding of CRMO's pathophysiology and optimal management remains limited.

Purpose of the Study:

  • To evaluate clinical characteristics of pediatric CRMO patients in Turkey.
  • To assess treatment options and response to anti-inflammatory therapies.
  • To identify factors influencing disease course and treatment outcomes.

Main Methods:

  • Retrospective review of 17 pediatric CRMO patients from two Turkish rheumatology centers.
  • Diagnosis confirmed via clinical findings, imaging, histopathology, and microbiology.
  • Data analysis included demographic, clinical features, and treatment responses.

Main Results:

  • Median age at diagnosis was 9.6 years; mean follow-up was 31.6 months.
  • Ten patients had recurrent multifocal disease, six had persistent, and one had a single episode.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) provided complete response in only one patient; 13 required further treatments including corticosteroids and biologics.
  • MEFV gene mutations were found in 4 patients, with improved symptoms on colchicine therapy.

Conclusions:

  • CRMO management in children often requires multi-drug approaches beyond NSAIDs.
  • Early diagnosis through clinical and imaging surveillance is crucial.
  • Ethnic variations may impact CRMO presentation and treatment response.